[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  ARS Pharmaceuticals [@ars_pharma](/creator/twitter/ars_pharma) on x XXX followers Created: 2025-07-18 13:38:52 UTC This content is intended for U.S. audiences only. #NEWS: Our licensing partner ALK has received approval in the United Kingdom for our treatment for allergic reactions (anaphylaxis). Read more: #AllergyCare #Investors $SPRY  XXX engagements  **Related Topics** [$spry](/topic/$spry) [united kingdom](/topic/united-kingdom) [Post Link](https://x.com/ars_pharma/status/1946203016828256495)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
ARS Pharmaceuticals @ars_pharma on x XXX followers
Created: 2025-07-18 13:38:52 UTC
This content is intended for U.S. audiences only.
#NEWS: Our licensing partner ALK has received approval in the United Kingdom for our treatment for allergic reactions (anaphylaxis).
Read more:
#AllergyCare #Investors $SPRY
XXX engagements
Related Topics $spry united kingdom
/post/tweet::1946203016828256495